BBI Solutions expands infectious disease reagent suite

BBI Solutions has demonstrated internal antibody development capabilities and has also expanded its infectious disease reagent suite

picture of

Breaking News

Cambrex expands generic API research capabilities

The specialist manufacturer of small molecule innovator and generic active pharmaceutical ingredients will expand its ...

Tonnes of regulatory grief solved by the experts at SWC

Süd-West-Chemie GmbH (SWC), which provides thermosetting resins to the pharma industry, has developed two new product ...

ADCs need more efficient manufacturing processes

Welsh ADC Biotechnology, a company working to simplify and lower production costs for anti-cancer blockbuster drugs, ...

Global partnership to expand pharma biocatalysis uptake

Codexis, Inc. and Porton Pharma Solutions recently announced a strategic collaboration to deploy Codexis’ world-leading ...

Omyapharm for enhanced ODTs

Study findings underline the pleasant mouthfeel and excellent technical properties of the high purity mineral excipient

Zai Lab and Crescendo Biologics enter exclusive global license agreement

Agreement will develop, commercialise and manufacture a topical, innovative antibody VH domain therapeutic for ...

Performance validation: HPAPI containment testing in a risk-based era

Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, ...

New risk assessment on safe levels of opium alkaloids in poppy seeds

The European Food Safety Authority (EFSA) updated its risk assessment of opium alkaloids in poppy seeds, confirming ...

Ardena acquires Syntagon

Contract development and manufacturing organisation acquires a specialist contract manufacturer of novel active ...

Formulating for the modern consumer

Selecting the right excipient to make the perfect capsule

Highly potent APIs: hazards in classification and handling

This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk ...

CordenPharma expands oligonucleotide API manufacturing

The expansion, which was completed in Q1 2018, will make the Colorado, US site one of the largest oligonucleotide ...

Sterling invests £6m into pilot plant

The contract development and manufacturing organisation is investing £6m into its pilot plant facility in the UK, to ...